Harvard Apparatus Regenerative Technology (HRGN) AI Stock Analysis

Harvard Apparatus Regenerative Technology

(Other OTC:HRGN)

Select Model

Rating:52Neutral

Price Target:$2.50▲(8.70% Upside)

Action:reiterated

Date:09/14/26

The score is held down primarily by weak financial performance (large losses, cash burn, and negative equity) and loss-driven valuation signals (negative P/E). These risks are partly offset by strong technical momentum (price above key moving averages with positive MACD) and a recent financing/note conversion that improves liquidity and modestly strengthens the balance sheet.

Positive Factors

Revenue GrowthThe sharp improvement in TTM revenue indicates that the company is generating more commercial activity than in prior periods. If this momentum persists, a larger revenue base could improve operating leverage and help the business absorb its currently heavy fixed cost structure.

Negative Factors

Severe UnprofitabilityThe company is producing losses that are extremely large relative to its revenue, with even gross profit remaining negative. This shows that the current operating model has not reached economic viability, and substantial improvement in pricing, costs, or scale is needed before revenue growth can translate into durable earnings.

Harvard Apparatus Regenerative Technology (HRGN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $40.44M
Dividend Yield: ―
Average Volume (3M): 2,341
Price to Earnings (P/E): -5.8
Beta (1Y): -0.11
Revenue Growth: 44.62%
EPS Growth: 9.81%
Country: US
Employees: 8
Sector: Consumer Defensive
Sector Strength: 62
Industry: Biotechnology

Harvard Apparatus Regenerative Technology Business Overview & Revenue Model

Company Description

Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal syste...

How the Company Makes Money

null

Harvard Apparatus Regenerative Technology Financial Statement Overview

Summary

Revenue improved (~93% YoY to ~$0.86M TTM), but profitability and cash generation remain very weak (negative gross margin, very large net losses vs. revenue, and negative operating/free cash flow). The balance sheet also deteriorated meaningfully with equity turning negative, increasing financing risk despite low absolute debt.

Income Statement

8Very Negative

Balance Sheet

22Negative

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Mar 2024	Dec 2022	Mar 2022
Income Statement
Total Revenue	859.00K	704.00K	0	0	0	0
Gross Profit	-49.00K	58.00K	-270.00K	-24.00K	0	0
EBITDA	-6.57M	-6.76M	-8.16M	-9.09M	-5.92M	-8.53M
Net Income	-6.68M	-6.87M	-7.73M	-9.02M	-6.07M	-7.98M
Balance Sheet
Total Assets	1.69M	2.68M	4.44M	2.61M	2.40M	1.87M
Cash, Cash Equivalents and Short-Term Investments	351.00K	1.35M	2.49M	432.00K	1.24M	1.24M
Total Debt	645.00K	199.00K	294.00K	48.00K	147.00K	169.00K
Total Liabilities	3.06M	1.62M	1.22M	968.00K	1.41M	4.89M
Stockholders Equity	-1.38M	1.06M	3.22M	1.65M	989.00K	-3.03M
Cash Flow
Free Cash Flow	-3.63M	-3.83M	-4.85M	-6.95M	-5.11M	-2.63M
Operating Cash Flow	-3.63M	-3.83M	-4.85M	-6.94M	-5.11M	-2.63M
Investing Cash Flow	0	0	0	-11.00K	-5,000	0
Financing Cash Flow	3.20M	2.70M	6.91M	6.14M	5.06M	2.84M

Harvard Apparatus Regenerative Technology Technical Analysis

Technical Analysis SentimentPositive

Last Price2.30

Price Trends

50DMA2.05Positive

100DMA1.60Positive

200DMA1.60Positive

Market Momentum

MACD0.01Positive

RSI59.77Neutral

STOCH63.73Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HRGN, the sentiment is Positive. The current price of 2.30 is above the 20-day moving average (MA) of 2.15, above the 50-day MA of 2.05, and above the 200-day MA of 1.60, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 59.77 is Neutral, neither overbought nor oversold. The STOCH value of 63.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HRGN.

Harvard Apparatus Regenerative Technology Risk Analysis

Harvard Apparatus Regenerative Technology disclosed 49 risk factors in its most recent earnings report. Harvard Apparatus Regenerative Technology reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Harvard Apparatus Regenerative Technology Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

HRGN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
HRGN	52Neutral	$46.65M	-5.79	-2019.03%	―	44.62%	9.81%
CELU	44Neutral	$25.96M	-0.45	142.25%	―	-58.14%	47.25%
LGVN	42Neutral	$5.32M	-0.17	-223.19%	―	-42.74%	20.66%
BRTX	38Underperform	$1.93M	-0.06	-423.84%	―	-8.47%	25.62%
PLUR	27Underperform	$15.64M	-0.51	144.63%	―	-23.95%	30.12%

* Consumer Defensive Sector Average

Performance Comparison

HRGN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HRGN	Harvard Apparatus Regenerative Technology Inc	2.30	0.33	17.05%
PLUR	Pluri Inc.	1.24	-2.45	-66.40%
BRTX	Biorestorative Therapies, Inc.	1.40	-28.60	-95.33%
CELZ	Creative Medical Technology Holdings, Inc.	0.66	-2.34	-78.17%
CELU	Celularity Inc.	0.80	-0.92	-53.49%
LGVN	Longeveron Inc.	1.67	-6.63	-79.89%

Harvard Apparatus Regenerative Technology Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Harvard Apparatus Regenerative Technology Completes Equity Financing Round

Positive

Sep 14, 2026

On September 11, 2026, Harvard Apparatus Regenerative Technology, Inc. completed a private placement of 2,703,727 shares of common stock, raising $2,838,911 at a price of $1.05 per share from a group of investors. The transaction provided fresh equit...

Private Placements and FinancingRegulatory Filings and Compliance

Harvard Apparatus Secures Second Insider Bridge Loan Financing

Neutral

Aug 3, 2026

On May 8, 2026, Harvard Apparatus Regenerative Technology, Inc. entered into a $200,000 bridge loan with its chairman and CEO, Junli He, under a note bearing 8% annual interest and maturing on the earlier of the next capital raise of at least $5 mill...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 14, 2026

Harvard Apparatus Regenerative Technology AI Stock Analysis